Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy.
Noboru KitamuraHitomi KobayashiYosuke NagasawaKaita SugiyamaHiroshi TsuzukiYutaka TanikawaNatsumi IkumiYuito OkadaYasuo TakahashiSatoshi AsaiNaoto TamuraMichihiro OgasawaraToshio KawamotoRyohei KuwatsuruHiromichi TamakiGenki KidoguchiMutsuto TateishiMakiko KimuraYuichi MochidaKengo HariganeTakayuki ShimazakiTakao KoikeKazuhide TanimuraHiroshi KataokaKoichi AmanoHidekata YasuokaMasami TakeiPublished in: International journal of rheumatic diseases (2023)
Attention should be given to RA patients with history of CVD, gastrointestinal disease, liver disease, or prior NSAIDs-use when considering MTX dose reduction to ensure benefits outweigh the risks of relapse.